REGN News

Levi & Korsinsky Urges Regeneron (REGN) Shareholders to Act Before Lead Plaintiff Deadline September 14, 2026

Portnoy Law Firm Announces Class Action on Behalf of Regeneron Pharmaceuticals, Inc. Investors

INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit

$REGN Lawsuit Notice: BFA Law Reminds Regeneron Investors of September 14 Lead Plaintiff Deadline After 9% Stock Drop Triggers Securities Fraud Class Action

REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Pomerantz LLP Alerts Shareholders to Investor Suit Against Regeneron Pharmaceuticals, Inc. – REGN

Liberate Bio Appoints Steven H. Bernstein, M.D., as Chief Medical Officer to Advance In Vivo Cell Programming Toward the Clinic

Pomerantz LLP Advises of Securities Class Action Against Regeneron Pharmaceuticals, Inc. – REGN

Shareholders of Regeneron Pharmaceuticals, Inc. (REGN): Protect Your Rights Before September 14, 2026 – Contact Levi & Korsinsky

REGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026 Ready to Announce with Confidence?